

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PRAXAIR DISTRIBUTION, INC.,  
Petitioner,

v.

INO THERAPEUTICS, LLC,  
Patent Owner.

---

Case IPR2015-00889  
Patent 8,573,209 B2

---

Before KEN B. BARRETT, MICHAEL J. FITZPATRICK, and  
SCOTT A. DANIELS, *Administrative Patent Judges*.

DANIELS, *Administrative Patent Judge*.

FINAL WRITTEN DECISION  
*35 U.S.C. § 318(a)*

Praxair Distribution, Inc. (“Praxair”) filed a Petition to institute an *inter partes* review of claims 1–7 of U.S. Patent No. 8,573,209 B2 (Ex. 1001, “the ’209 patent”). Paper 1 (“Pet.”).<sup>1</sup> We instituted trial for claims 1–7 of the ’209 patent on certain grounds of unpatentability asserted in the Petition. Paper 14 (“Decision to Institute” or “Inst. Dec.”). After institution of trial, Patent Owner, INO Therapeutics, LLC (“Patent Owner” or “INO”) filed a Patent Owner Response. Paper 30 (“PO Resp.”). Praxair timely filed a Reply. Paper 40 (“Reply”).

A consolidated hearing for this proceeding as well as IPR2015-00884, IPR2015-00888, IPR2015-00891, and IPR2015-00893, each involving Praxair and INO but different patents, was held on May 16, 2016. The transcript of the consolidated hearing has been entered into the record. Paper 53 (“Tr.”).

Also before the Board is INO’s Motion to Exclude Evidence (Paper 44), Praxair’s Opposition to the same (Paper 48), and INO’s Reply (Paper 49).

After considering the evidence and arguments of counsel and for the reasons set forth below, we determine that Praxair has not met its burden of showing that claims 1–7 of the ’209 patent are unpatentable. We dismiss INO’s Motion to Exclude as moot.

---

<sup>1</sup> The ’209 Patent is the subject of litigation captioned *INO Therapeutics LLC et al v. Praxair Distribution Inc. et al.*, 1:15-cv-00170-GMS currently pending in the District Court for the District of Delaware.

## I. BACKGROUND

### A. The '209 Patent (Ex. 1001)

The '209 patent (Ex. 1001), titled “Gas Delivery Device and System,” relates generally to a gas delivery system, and a method for administering therapy gas, such as nitric oxide (NO), to a medical patient. Ex. 1001, (54), 1:5–17, Fig. 1. The gas delivery system includes valve assembly 100 having valve 107 shown below in wireless communication with control module 200. *Id.* at 4:65–67, Fig. 1.




Figure 1 of the '209 patent, above, depicts a diagrammatic representation of a gas delivery system for administering therapy gas from gas source 50 (i.e., a tank to which the valve assembly is mounted) through valve 107 and via control module 200 to a patient. *Id.* at 5:41–63. In the delivery system, administration of therapy gas to the patient is regulated by control module 200 to a medical device for introducing gas to the patient (e.g., ventilator 400, nasal cannula, endotracheal tube, face mask, etc.). *Id.* Gas is initially supplied to control module 200 from gas source via valve assembly 100 by opening valve 107.

Valve assembly 100 is shown in greater detail in Figures 2 and 3 reproduced below.

FIG. 2




FIG. 3




Figure 2 depicts valve assembly 100 and actuator 114, a rotatable knob or handle, for opening and closing valve 107 that is connected between gas source 50 and control module 200. Figure 3 illustrates an exploded view of actuator 114. As best observed in Figure 3 above, the valve assembly includes circuit 150 disposed in actuator 114. *Id.* at 5:64–66. The circuit communicates with the control module, for example via a wired or wireless link, by valve transceiver 120. *Id.* at 5:64–6:6.

Illustrated by Figure 4 of the '209 patent, below, is a block diagram of circuit 150.




Figure 4 depicts various components of circuit 150 including, *inter alia*, valve processor 122, memory 134, valve transceiver 120, power source 130, and valve display 132.<sup>2</sup>

The primary purpose of circuit 150 and valve processor 122 is not to open or close the valve, but to communicate to control module 200 gas data, specifically gas identification, gas expiration date, and gas concentration.

<sup>2</sup> In Figure 4, timer component apparently is mislabeled as 134, and recited in the specification as reference number 124.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.